- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04673695
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344
December 16, 2020 updated by: Chong Kun Dang Pharmaceutical
An Open Label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Adult Volunteers
A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-344
Study Overview
Detailed Description
A Phase 1 Clinical Trial to evaluate the safety and pharmacokinetics in healthy adult volunteers after administration of CKD-344.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yook-Hwan Noh, M.D., PhD.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Yook-Hwan Noh
-
Contact:
- Yook-Hwan Noh
- Phone Number: +827046659174
- Email: yook.noh@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult volunteers aged ≥ 19 years
- Weight ≥60kg, with calculated body mass index(BMI) of 18 to 30 kg/m2
- Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.
- Those who are eligible for clinical trials based on laboratory (hematology, blood coagulation, blood chemistry, serology, urinalysis) at screening.
- Those who agree to contraception during the participation of clinical trial.
- Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.
Exclusion Criteria:
- Those who has a medical evidence or a history of clinically significant gastrointestinal, cardiovascular, endocrine, pulmonary, hematological, infective disease, renal, urinary, psychiatric, neurologic, skeleto-muscular, immune, etc.
- Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.
- Those who had taken prescription or nonprescription drugs within 10 days prior to the first dose of investigational product.
- Those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs.
- Those who donated whole blood within 2 months or blood components within 1 month prior to the first dose of the investigational product.
- Those who exceed an alcohol and cigarette consumption than below criteria. A. Alcohol: Man- 21 glasses/week, Woman - 14 glasses/week B. Smoking: 20 cigarettes/day
- Those who exceeds 2 times the upper limit of the reference range of AST(or ALT) or 1.5 times the upper limit of the reference range of γ-GTP.
- Those who have hypersensitivity to the drug or the drug ingredient, such as anaphylactic reactions.
- Those who have specific disease(e.g. severe bleeding disorder, severe renal/hepatic disease, uncontrolled severe hypertension, etc.)
- Those who were deemed inappropriate to participate in the study by the investigator.
- Those who have a pregnant or nursing woman.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group A
|
NOAC(Factor Xa inhibitor)
Other Names:
NOAC(Factor Xa inhibitor)
Other Names:
|
EXPERIMENTAL: Group B
|
NOAC(Factor Xa inhibitor)
Other Names:
NOAC(Factor Xa inhibitor)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCt(Area Under Curve last) of CKD-344
Time Frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose
|
Area under the plasma concentration time curve of CKD-344, from time zero up to the last measurable concentration.
|
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose
|
Cmax
Time Frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose
|
The maximum concentration observed of CKD-344 over blood sampling time.
|
predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Yook-Hwan Noh, H plus Yangji Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 13, 2020
Primary Completion (ANTICIPATED)
December 26, 2020
Study Completion (ANTICIPATED)
January 2, 2021
Study Registration Dates
First Submitted
November 8, 2020
First Submitted That Met QC Criteria
December 16, 2020
First Posted (ACTUAL)
December 17, 2020
Study Record Updates
Last Update Posted (ACTUAL)
December 17, 2020
Last Update Submitted That Met QC Criteria
December 16, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- A109_01BE2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anticoagulant
-
Blau Farmaceutica S.A.Not yet recruiting
-
University Hospital, LilleTerminated
-
HemCon Medical Technologies, IncWithdrawnAnticoagulant Therapy
-
Blau Farmaceutica S.A.Not yet recruiting
-
Groupe Hospitalier Paris Saint JosephCompleted
-
University Hospital, Strasbourg, FranceRecruiting
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
Johann Wolfgang Goethe University HospitalUnknownAnticoagulant Prophylaxis/TherapyGermany
-
Vascular Solutions LLCWestat; United States Army Medical Materiel Development ActivityNot yet recruitingAnticoagulant ReversalUnited States
-
Hadassah Medical OrganizationUnknown
Clinical Trials on Lixiana(D006)
-
Chong Kun Dang PharmaceuticalRecruitingAnticoagulantKorea, Republic of
-
Dong-A ST Co., Ltd.Completed
-
Galaxia EmpíricaRecruitingAuricular FibrillationSpain
-
Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo...CompletedAtrial FibrillationThailand
-
Daiichi Sankyo, Inc.CompletedAtrial Fibrillation | Venous Thromboembolism
-
Daiichi Sankyo, Inc.CompletedVenous ThromboembolismTaiwan, Korea, Republic of
-
Insel Gruppe AG, University Hospital BernCompletedIschaemic StrokeBelgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyCompletedVenous ThromboembolismGermany
-
Daiichi Sankyo, Inc.CompletedAtrial FibrillationKorea, Republic of, Taiwan
-
Jong Sung KimDong-A University Hospital; Soon Chun Hyang University; Kyung Hee University...CompletedAcute Ischemic StrokeKorea, Republic of